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Identity 
Other names: hsa-mir-100, MIRN100, miR-100 
HGNC (Hugo): MIR100 
Location: 11q24.1 
Local order 
- microRNA 125b-1 
- BH3-like motif containing, cell death inducer 
- microRNA let-7a-2 
- microRNA 100 
- Glutamate-ammonia ligase (glutamine synthetase) 
pseudogene 3 
- Ubiquitin associated and SH3 domain containing B 
Note 
Human chromosome 11 (HSA11), is one of the most 
gene- and disease-rich chromosomes in humans with a 
gene density of 11,6 genes per megabase, including 
1524 protein-coding, and 69 
 microRNAs. It represents approximately 4,4% of the 
human genome. There are hundreds of disorders 
currently attributed to the chromosome, including 
cancer susceptibility loci. 





Their predicted targets are: 
SMARCD1, SMARCA5, mTOR, PPFIA3 (Sun et al., 
2011; Nagaraja et al., 2010), PLK1 (Petrelli et al., 
2012; Peng et al., 2012; Feng et al., 2011; Ugras et al., 
2011; Li et al., 2011; Shi et al., 2010), CTDSPL 
(RBSP3) (Zeng et al., 2012), β-tubulin (Lobert et al., 
2011), ATM (Ng et al., 2010), PPP3CA (Sylvius et al., 
2011), FGFR3 (Cato et al., 2009). 











RNA - stem-loop. 
Description 





Mature sequence: 13 - aacccguagauccgaacuugug - 34. 
Protein 
Note 
microRNAs are not translated into amino acids. 
Mutations 
Note 






miR-100 is down-regulated during the prostate cancer 
progression, from high grade prostate intraepithelial 
neoplasia through metastasis (Leite et al., 2011a; Leite 
et al., 2011b). The same result was posteriorly 
confirmed by Sun D et al. (2011) that found miR-100 
down-expressed in C4-2B, an advanced prostate cancer 
cell line in comparison with LNCaP an androgen-
dependent prostate cancer cell line. Porkka KP et al. 
have previously related down-expression of miR-100 
with hormone-refractory tumors (Porkka et al., 2007). 
Prognosis 
Contradictorily, lower levels of miR-100 was related to 
lower rates of biochemical recurrence in patients with 
localized adenocarcinoma treated with radical 
prostatectomy in a mean follow up of 58,8 months 
(Leite et al., 2011c). 
Hepatocellular carcinoma 
Disease 
miR-100 is involved with HCC carcinogenesis being 
down-regulated early, since the pre-neoplastic lesions. 
A paralleled increase in polo like kinase 1 (PLK1)  
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suggests this gene as a target of this miR-100 (Petrelli 
et al., 2012). 
Ovarian cancer 
Disease 
In a microarray study of 74 ovarian cancer tissue and 
cell lines miR-100 was shown to be down-regulated in 
cancer specimens against normal tissue together with 
miR-199a, miR-140, miR-145, and miR-125b1 (Iorio et 
al., 2007). 
Prognosis 
miR-100 is significantly down-expressed in epithelial 
ovarian cancer and related to FIGO stage, lymph node 
metastasis, higher CA125 serum levels and shorter 
overall survival (Peng et al., 2012). Experimental 
studies with clear cell type ovarian cancer, an 
aggressive variant of the tumor showed that over-
expression of miR-100 enhanced sensitivity to the 
rapamycin analog RAD001 (everolimus), confirming 
the key relationship between mir-100 and the mTOR 
pathway (Nagaraja et al., 2010). 
Lung cancer 
Note 
Drug resistance - miR-100 was shown to be down-
regulated in docetaxel-resistant SPC-A1/DTX cells 
compared with parenteral SPC-A1 cells.  
The ectopic miR-100 re-sensitized tumor cells to 
docetaxel by suppression of cell proliferation, G2/M 
arrest and induction to apoptosis.  
Similar effect was identified knocking down PLK1, 




In acute myeloid leukemia (AML) miR-100 was found 
to promote cell proliferation of promyelocytic blasts 
and arrest the differentiation to granulocyte/monocyte 
lineages. RBSP3, a phosphatase-like tumor suppressor, 
important in cell differentiation is a target of miR-100. 
miR-100 regulates G1/S transition and blocks the 
terminal differentiation of cells targeting RBSP3 which 
in turn modulates pRB/E2F1 (Zeng et al., 2012). 
Prognosis 
Differently in acute lymphoblastic leukemia (ALL) 
miR-100 is down-regulated when compared to normal 
samples.  
Also the down-expression is related to higher count of 
white blood cells and hyperdiploid karyotypes. Increase 
in miR-100 expression is related to t(12;21), biological 
feature associated to better outcome (de Oliveira et al., 
2012).  
On the other hand miR-100 over-expression has been 
related to vincristine and daunorubicin resistance 




miRNA profile was used to differentiate benign and 
malignant thyroid tumors in specimens obtained by 
fine-needle aspiration biopsy. Diagnostic accuracy of 
differentially expressed genes was determined by 
analyzing receiver operating characteristics (ROC). 
miR-100 was overexpressed in malignant follicular 




miR-100 was shown to be over-expressed in chronic 
pancreatitis when compared with normal pancreas and 
also over-expressed in pancreatic cancer versus 
pancreatitis (Bloomston et al., 2007). 
Breast cancer 
Note 
Drug resistance - Taxanes bind to β subunit of the 
tubulin heterodimer and reduce microtubule dynamics 
leading to cell cycle arrest in G2/M. miR-100 is 
involved in the regulation of the expression of β-tubulin 
class II and V, and a down-expression of miR-100 is 
related to increase in the expression of these isoforms 
of β-tubulin conferring MCF7 breast cancer cell line 
resistance to paclitaxel (Lobert et al., 2011). 
Disease 
miR-100 has been described as down-regulated in 




Down-regulation of miR-100 has been described in 
urothelial carcinomas, having as a main target the 
mRNA of FGFR3. FGFR3 mutation is characteristics 
of low-grade, non-invasive urothelial carcinoma, and 
another possible pathway for bladder cancer 
development would be the loss of regulation of FGFR3 
by down-expression of miR-100 (Dip et al., 2012 in 
press; Song et al., 2010; Catto et al., 2009). 
Head and neck squamous cell 
carcinoma 
Note 
Drug resistance - Down-regulation of miR-100 together 
with miR-130a and miR-197 was related to resistance 
of UMSCC-1 and SQ20B cell lines to cisplatin, 5-
fluorouracil, paclitaxel, methotrexate, and doxorubicin 
(Dai et al., 2010). 
Glioma 
Note 
Radio resistance - Higher expression of miR-100 
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confers radio-sensitivy to M059J and M059K human 
malignant glioma cells, targeting ATM (Ng et al., 
2010). 
Uterine cervix squamous carcinoma 
Disease 
The miR-100 expression was shown to be significantly 
and gradually reduced from low-grade CIN, high-grade 
CIN to cervical cancer tissues. It was also reduced in 
HPV positive cervical cancer cell lines. miR-100 down-
expression influenced cell proliferation, cycle and 
apoptosis, and the probable mechanism is the loss of 
control of PLK1 protein (Li et al., 2011). 
Laminin A/C - related muscular 
dystrophy 
Note 
Physiopathology - miR-100, toghether with miR-192, 
and miR-335 participate in muscle differentiation and 
proliferation and are probably involved in the 
development of the disease. miR-100 expression 
induces up-regulation of myogenin and α-actin and 
down-regulates Ki-67 a protein related to proliferation. 
Sylvius et al. (2011) show that miR-100 is involved 
with muscle differentiation by targeting PPP3CA the 
calcineurin gene. Calcineurin is a component of the 
calcium-dependent signaling pathways and has been 
shown to be involved in the regulation of skeletal 




Physiopathology - mir-100 has been described as 
down-regulated in psoriasis skin. It is probably 
involved in the disease by repressing mTOR and 
inhibiting angiogenesis. In this context, miR-100 has 
been called as a anti-angiomiR (Calin et al., 2011). 
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